Prelude Therapeutics, with ticker symbol PRLD, has announced the publication of two abstracts featuring promising preclinical data from their studies on selective inhibitors targeting the JAK2V617F mutant and CALR-targeted degrader antibody conjugates, known as DACs. These findings have been selected for oral presentation during the American Society of Hematology's (ASH) 67th Annual Meeting. The event is scheduled to occur in Orlando, Florida, from December 6-9, 2025. Full details of the abstracts are available on the ASH Annual Meeting & Exposition website for 2025.
Prelude Therapeutics Inc is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor; PRT3645, a next-generation CDK4/6 inhibitor; and PRT3789, a first-in-class SMARCA2/BRM protein degrader. Operating within the biotechnology industry, Prelude Therapeutics is positioned in the healthcare sector with a market capitalization of approximately $90 million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.